CVR Medical Corp :. Announces Resignation of CEO and Financial Advisor

VANCOUVER, BC - CVR Medical Corp. (CVM.V) (TSXV: CVM) (OTCQB: CRRVF) ('CVR Medical' or the 'Company' or 'we') a Canadian listed and US based healthcare company in the medical device market is announcing the resignation of Michael Rhodes, Chief Executive Officer (CEO) of CVR Medical Corp. and Harvey McKenzie, Financial Advisor and nominee to the Board of Directors of CVR Medical Corp. The Board has commenced an executive search process to identify a new permanent CEO. Message from Michael: 'Four weeks ago, we announced an amended restructuring agreement with CVR Global Inc. I encouraged you, our shareholders, to reach out to me so that I could explain the details of the restructuring agreement and answer any questions that you may have. I was delighted that many of you took the opportunity via Zoom, telephone, and email. You spoke, I listened, and with the support of Harvey McKenzie and the Board, we developed a set of terms that we believe creates a company that has a path to market that is unencumbered and therefore worthy of further investment. Unfortunately, CVR Global Inc. was not immediately agreeable to all of the terms. It is therefore, with great regret that I resign my position as CEO, however, the Board is working diligently on the agreement and plans to move the company ahead. I wish the Company and the shareholders every success for the future and take this opportunity to thank the Board of Directors for their support.

About CVR Medical

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan device ('CSS'). The CSS is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR Medical's shares are listed on the OTCQX under the symbol 'CRRVF'. The Company is listed for trading under the symbol 'CVM'. Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com

Contact:

Paul Blunden, M.D.

President/ Director

interim CEO and CFO

Email: info@cvrmed.com

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to: trading on and dialogue with the Exchange, communications and negotiations with CVR Global, dialogue with certain advisors, the Proposed Restructuring, the License Agreement, the Review, certain corporate and securities law requirements, raising capital and potential litigation. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forwardlooking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a failure or material setback in the Company satisfying the remaining conditions outlined by the TSX-V; (2) a failure of the Company to raise sufficient capital to relaunch the Company; (3) an inability to complete the Proposed Restructuring with CVR Global: (4)a downturn in general economic conditions in North America and internationally; (5)the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine; (6) a change in health regulations; (7) any number of events or causes which may delay or cease commercialization and development of the CSS Device; (8) the risk that the Company does not execute its business plan; (9) the risk of litigation between the Company and certain shareholders and the risk of litigation generally; (10) an inability to retain key employees; (11) an inability to finance operations and growth; (12) compliance with certain corporate and securities law requirements; and (13) other factors that are beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.